{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Measure exhaled nitric oxide', '-', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast', 'of > 1 hour.', 'Perform spirometry', '-', 'Spirometry will be performed at approximately the same time of last visit after a wash', 'out period of bronchodilators according to their action duration, for example,', 'withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at', 'least 6 hours, withholding the last dose of LABA for at least 12 hours, and withholding', 'the last dose of LAMA for at least 24 hours. This will be verified before performing', 'the PEF measurements.', 'Download electronic diary/PEF meter and remind patient to bring the device to the next', 'visit', 'Remind parent(s)/caregiver(s)/legal guardian(s) to use salbutamol/albuterol or', 'levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct them to', 'record usage in the electronic diary.', 'Remind parent(s)/caregiver(s)/legal guardian(s) to continue the stable dose of ICS in', 'combination with a second controller which was maintained over the randomized', 'treatment period (unless treatment modified based on medical judgment) and record daily', 'usage in the electronic diary.', 'Remind parent(s)/caregiver(s)/legal guardian(s) to withhold bronchodilators according to', 'their action duration, for example, withholding the last dose of salbutamol/albuterol or', 'levosalbutamol/levalbuterol for at least 6 hours, withholding the last dose of LABA for at', 'least 12 hours, and withholding the last dose of LAMA for at least 24 hours. This will be', 'verified before performing the PEF measurements.', 'Schedule a site visit 4 weeks later ( 5 days) and ask patient to come in at approximately', 'the same time of this visit', '10.1.15', 'Visit 31 (Week 64, End of Study Visit)', 'Record all concomitant medication use; inquire about AEs/SAEs and background asthma', 'therapy tolerability', 'Measure vital signs (blood pressure, heart rate, respiratory rate, body temperature, weight', 'and height)', 'Perform physical examination', 'Obtain urine for urinalysis (dipstick)', 'Assess menstruation status and perform urine dipstick pregnancy test for female patients', 'of childbearing potential (who have commenced menstruating)', 'Administer ACQ-7', 'Administer all additional PROs:', 'PAQLQ(S)-IA, PRQLQ-IA, EQ-5D-Y for children, PACQLQ', 'Property of the Sanofi Group - strictly confidential', 'Page 96', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Administer HCRU', 'Measure exhaled nitric oxide', '-', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast', 'of > 1 hour.', 'Perform spirometry', '- Spirometry will be performed at approximately the same time of last visit after a wash', 'out period of bronchodilators according to their action duration, for example,', 'withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at', 'least 6 hours, withholding the last dose of LABA for at least 12 hours, and withholding', 'the last dose of LAMA for at least 24 hours. This will be verified before performing', 'the PEF measurements.', '-', 'Post-bronchodilator FEV1 should be determined.', 'Perform 12-lead ECG', 'Perform blood sampling for the following tests:', '-', 'Clinical laboratories,', '-', 'Systemic drug concentration,', '-', 'ADAs', 'Download electronic diary/PEF meter and take back the device', 'Call IVRS/IWRS to register the EOS date', '10.2 DEFINITION OF SOURCE DATA', 'Source data is all information in original records and certified copies of original records of clinical', 'findings, observations, or other activities in a clinical trial necessary for the reconstruction and', 'evaluation of the trial. Source data are contained in source documents. Source documents are', 'original documents, data and records such as hospital records, clinic and office charts, laboratory', 'notes, memoranda, pharmacy dispensing records, recorded data from automated instruments, etc.', 'All the data collected in the e-CRF should be transcribed directly from source documents. Data', 'downloaded from the study-associated central laboratories, spirometry, nitric oxide measurement,', 'ECG, and patient electronic diary/PEF meter will be considered source data.', '10.3 HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT', 'DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION', 'The IMP should be continued whenever possible. In case the IMP is stopped, it should be', 'determined whether the stop can be made temporarily; permanent IMP discontinuation should be', 'a last resort. Any IMP discontinuation should be fully documented in the e-CRF. In any case, all', 'efforts should be made to maintain the patient for the 12 weeks follow up.', 'Property of the Sanofi Group - strictly confidential', 'Page 97', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}